According to a recent LinkedIn post from Dispatch Bio, the company’s Chief Scientific Officer, Barbra Sasu, is scheduled to present at the 2026 Society for Immunotherapy of Cancer Spring Scientific meeting focused on next‑generation cell therapies, T cell engagers, and combination approaches. The post indicates that her presentation will address synthetic antigen strategies intended to enable universal immunotherapies across solid tumors and to tackle targeting and resistance challenges in immunotherapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post further suggests that Dispatch Bio views engagement with the broader immuno‑oncology community as an important component of its development strategy. For investors, participation in a high‑profile scientific forum may provide incremental validation of the company’s technology platform, potentially enhancing its visibility to partners and investors in the competitive solid‑tumor immunotherapy space, although no direct financial milestones or timelines are mentioned.